يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Poor performance ECOG 2&3"', وقت الاستعلام: 0.78s تنقيح النتائج
  1. 1
    The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy

    المؤلفون: Robin M. Rudd, Richard Jones, Alex Edwards, Siow Ming Lee, Matthew Hatton, Allan Hackshaw, Geraldine Skailes, Elizabeth Toy, Yenting Ngai, Sunil Upadhyay, Penella J. Woll, Stephen Falk, Rohit Lal, Conrad R. Lewanski

    المصدر: European Journal of Cancer

    مصطلحات موضوعية: Male, Proteomics, 0301 basic medicine, Oncology, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Predictive, 0302 clinical medicine, Non-small cell lung cancer, Poor performance ECOG 2&3, Carcinoma, Non-Small-Cell Lung, VeriStrat, Medicine, Aged, 80 and over, Predictive marker, Hazard ratio, Blood Proteins, Middle Aged, Survival Rate, Proteonomic, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Biomarker (medicine), Female, Erlotinib, Veristrat, medicine.drug, medicine.medical_specialty, Adenocarcinoma of Lung, Prognostic, Placebo, Article, Erlotinib Hydrochloride, 03 medical and health sciences, Double-Blind Method, Predictive Value of Tests, Internal medicine, Biomarkers, Tumor, Humans, Lung cancer, Protein Kinase Inhibitors, Aged, Platinum, Chemotherapy, business.industry, Biomarker, medicine.disease, Active supportive care, 030104 developmental biology, business, Follow-Up Studies

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a7843ac98a551237a56e4062a17ef85
    https://doi.org/10.1016/j.ejca.2019.07.025

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية

    لا يتم عرض هذه النتيجة على الضيوف.

    View record in Scopus
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء